Healthcare Dominates HK VolumeSurge; Record Margins Meet BIOSECURE Overhang — Quick Take
Healthcare absolutely dominated today's HK VolumeSurge screener — 26 out of 50 passing stocks, more than triple the next largest sector. WuXi Biologics (2269.HK) was the #1 pick by turnover at HKD 3.5 billion, surging +10.8% with 76.3 million shares traded. This comes as the daily financial summary calls for structural mainland capital inflows into HK equities ($8B inflow reported), and WuXi Bio is heading into its H1 2026 interim results board meeting on August 25 — a clear catalyst window. The stock is up ~40% over 52 weeks but still trades at a forward P/E of just 25x against a 16%+ growth runway, suggesting the BIOSECURE Act discount may be overdone.
| Year | Revenue (RMB B) | Rev Growth | Gross Margin | Net Profit Attr. (RMB B) |
|---|---|---|---|---|
| 2022 | 15.27 | +48.4% | 44.0% | 4.42 |
| 2023 | 17.03 | +11.6% | 40.1% | 3.40 |
| 2024 | 18.68 | +9.6% | 41.0% | 3.35 |
| 2025 | 21.80 | +16.7% | 46.0% | 4.90 |
* 2025 continuous ops revenue grew >20% YoY. IFRS net profit rose 45.3% to RMB 5.7B. EBITDA margin hit 41.5%. Gross margin expanded 500 bps driven by capacity utilisation and WBS efficiency. Free cash flow reached RMB 2.3B (+70% YoY).
WuXi Biologics operates a fully integrated CRDMO (Contract Research, Development and Manufacturing Organization) platform — essentially an end-to-end outsourced engine for biologic drug development. Its "Follow and Win the Molecule" strategy starts with early-stage research, captures molecules as they progress through clinical trials, and locks in long-term manufacturing contracts.
Key metrics as of FY2025: 945 total integrated projects, 74 late-stage (Phase III), 25 commercial manufacturing programs, a record 209 new integrated projects signed in 2025. The backlog stands at US$23.7 billion, with US$4.5 billion due within 3 years. Bispecifics and ADCs now account for 2/3 of new signings, with bispecific revenue growing 120%+ YoY — now contributing nearly 20% of total revenue.
WuXi Biologics is executing at its best level since the 2022 COVID-era peak — record gross margins, accelerating continuous ops growth above 20%, and a pipeline that any global CDMO would envy. The August 25 H1 2026 board meeting is a near-term catalyst, and the business momentum heading into it looks strong. The problem is that none of this matters if the BIOSECURE Act names them on the 1260H list. That binary event dominates everything. For investors willing to bet the political outcome stays contained — that WuXi's US manufacturing footprint, global client diversification, and the practical impossibility of replacing 945 projects of CDMO capacity overnight — it's an interesting risk/reward at 25x forward earnings. For everyone else, it's a watch-and-wait until the DoD list drops.
Disclaimer: AI-generated quick take for informational purposes only. Not investment advice. Data from public filings and financial data providers. Estimates marked where historical detail was unavailable from press releases.